{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:37:08Z","timestamp":1787315828399,"version":"build-2736575974"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["MRF2012410"],"award-info":[{"award-number":["MRF2012410"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022869","name":"The Royal Australian and New Zealand College of Psychiatrists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pnpbp.2026.111642","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:40:29Z","timestamp":1770741629000},"page":"111642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Psychedelics in functional disorders: A scoping review"],"prefix":"10.1016","volume":"145","author":[{"given":"Chiranth","family":"Bhagavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orwa","family":"Dandash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111642_bb0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00011","article-title":"A review of the evidence for overlap among unexplained clinical conditions","volume":"134","author":"Aaron","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2025.1527783","article-title":"Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial","volume":"6","author":"Aday","year":"2025","journal-title":"Front. Pain Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0020","series-title":"DSM-5 Diagnostic Classification. Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000139775","article-title":"Clinical studies of lysergic acid diethylamide","volume":"128","author":"Anderson","year":"1954","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2024.1346053","article-title":"Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies","volume":"5","author":"Armstrong","year":"2024","journal-title":"Front. Pain Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0035","series-title":"The Use of LSD in Psychotherapy and Alcoholism","article-title":"LSD psychotherapy; LSD psycho-exploration: three reports","author":"Baker","year":"1967"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","article-title":"The emerging field of psychedelic psychotherapy","author":"Barber","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0033-3182(92)72018-0","article-title":"Amplification, somatization, and the somatoform disorders","volume":"33","author":"Barsky","year":"1992","journal-title":"Psychosomatics"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/nc\/niy008","article-title":"Dimensions of Consciousness and the Psychedelic State","volume":"2018","author":"Bayne","year":"2018","journal-title":"Neurosci. Conscious."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0055","first-page":"1","article-title":"Psilocybin and motor function: a triple-blind, dose-finding study in healthy participants","author":"Bhagavan","year":"2024","journal-title":"Psych Res. Clin. Pract."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0060","first-page":"1","article-title":"Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study","author":"Bhagavan","year":"2025","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0065","article-title":"A randomised, triple-blind, dose-finding study of the impact of psilocybin on motor function in healthy participants","author":"Bhagavan","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0070","series-title":"An Experiment with a Psychiatric Night Hospital","author":"Bierer","year":"1960"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0075","first-page":"637","article-title":"Marlborough night hospital: treatment with LSD and group therapy","volume":"57","author":"Bierer","year":"1961","journal-title":"Nurs. Times"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2025.2478097","article-title":"Therapeutic potential of psilocybin for treating neuropsychiatric long COVID symptoms: a Reddit investigation","author":"Bobak","year":"2025","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/20494637221114962","article-title":"Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey","volume":"16","author":"Bonnelle","year":"2022","journal-title":"Br. J. Pain"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.735427","article-title":"Self-medication for chronic pain using classic psychedelics: a qualitative investigation to inform future research","volume":"12","author":"Bornemann","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1320780","article-title":"Study protocol for \u201cPsilocybin in patients with fibromyalgia: brain biomarkers of action.\u201d","volume":"15","author":"Bornemann","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpsychores.2015.01.003","article-title":"The common link between functional somatic syndromes may be central sensitisation","volume":"78","author":"Bourke","year":"2015","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2025.2577311","article-title":"Psychedelic use and intimacy: a systematic review of experimental and naturalistic research","author":"Bradford","year":"2025","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0110","first-page":"422","article-title":"5-HT2A agonists: a novel therapy for functional neurological disorders? International Journal of Neuropsychopharmacology","volume":"20","author":"Bryson","year":"2017"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-1505-4","article-title":"Functional somatic disorders: discussion paper for a new common classification for research and clinical use","author":"Burton","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0120","first-page":"241","article-title":"LSD 25 as an aid in psychotherapy; preliminary report of a new drug","volume":"11","author":"Busch","year":"1950","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0125","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320912125","article-title":"Psychedelic treatment of functional neurological disorder: a systematic review","author":"Butler","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1176\/appi.neuropsych.21080213","article-title":"Views on using psychoactive substances to self-manage functional neurological disorder: online patient survey results","volume":"35","author":"Butler","year":"2023","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.12688\/wellcomeopenres.22543.1","article-title":"Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol","volume":"9","author":"Butler","year":"2024","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0140","doi-asserted-by":"crossref","DOI":"10.1556\/2054.2024.00350","article-title":"Psychedelic use and psychological flexibility: the role of meaningful intention and decentering","author":"Campo","year":"2024","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0150","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0155","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: A review and proposed mechanism of action","author":"Castellanos","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0160","first-page":"1303","article-title":"P-29 Psychedelic-assisted psychotherapy for fibromyalgia: the therapeutic process of a fibromyalgia patient up until 6 months after a psychedelic retreat","volume":"42","author":"Cavarra","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ejp.2171","article-title":"Potential analgesic effects of psychedelics on select chronic pain conditions: a survey study","volume":"28","author":"Cavarra","year":"2024","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0170","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archpsyc.1960.03590090042008","article-title":"Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy","volume":"2","author":"Chandler","year":"1960","journal-title":"AMA Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.8791","article-title":"Long-COVID symptoms improved after MDMA and psilocybin therapy: a case report","volume":"12","author":"Chopra","year":"2024","journal-title":"Clin. Case Reports"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2023.111163","article-title":"Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?","volume":"179","author":"Chupin","year":"2023","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0185","series-title":"Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders","year":"2024"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jpsychores.2009.09.004","article-title":"Is there a better term than \u201cmedically unexplained symptoms\u201d?","author":"Creed","year":"2010","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0195","series-title":"Medically Unexplained Symptoms, Somatisation and Bodily Distress: Developing Better Clinical Services","first-page":"1","article-title":"Epidemiology: Prevalence, Causes and Consequences","author":"Creed","year":"2011"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0200","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/BF01562041","article-title":"Analytic work with LSD 25","volume":"33","author":"Cutner","year":"1959","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0205","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0210","first-page":"511","article-title":"Lysergide in the treatment of neurosis.(a report of two cases)","volume":"27","author":"Denson","year":"1966","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1192\/bjp.116.533.443","article-title":"A controlled study of LSD treatment in alcoholism and neurosis","volume":"116","author":"Denson","year":"1970","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2296-8-33","article-title":"Patients with persistent medically unexplained symptoms in general practice: characteristics and quality of care","volume":"8","author":"Dirkzwager","year":"2007","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-66685-4","article-title":"Comorbidities of patients with functional somatic syndromes before, during and after first diagnosis: a population-based study using Bavarian routine data","volume":"10","author":"Donnachie","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0230","first-page":"557","article-title":"The effects of psilocybine in a case of hysteria","volume":"38","author":"Duche","year":"1962","journal-title":"Sem. Hop. Ther. Paris"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0235","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jpain.2022.05.003","article-title":"If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics","volume":"23","author":"Dworkin","year":"2022","journal-title":"J. Pain"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0240","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/brain\/aws129","article-title":"A Bayesian account of \u201chysteria.\u201d","volume":"135","author":"Edwards","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0245","doi-asserted-by":"crossref","unstructured":"Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J. Nerv. Ment. Dis. LWW; 1958;127:528\u201339.","DOI":"10.1097\/00005053-195812000-00006"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2021.12.005","article-title":"Beating pain with psychedelics: matter over mind?","author":"Elman","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0255","series-title":"Functional Ophthalmic Disorders: Ocular Malingering and Visual Hysteria","first-page":"1","article-title":"Terminology of functional disorders","author":"Enzenauer","year":"2014"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0260","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2018.1264","article-title":"Current concepts in diagnosis and treatment of functional neurological disorders","author":"Espay","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jpsychores.2010.02.004","article-title":"One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders","volume":"68","author":"Fink","year":"2010","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/PSY.0b013e31802e46eb","article-title":"Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients","volume":"69","author":"Fink","year":"2007","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0275","first-page":"1","article-title":"Serotonergic psychedelics temporarily modify information transfer in humans","volume":"18","author":"Francesc Alonso","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrn2787","article-title":"The free-energy principle: a unified brain theory?","author":"Friston","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default mode network modulation by psychedelics: a systematic review","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0290","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1600-0447.1964.tb04949.x","article-title":"LSD-TREATMENT: experience gained within a three-year-period","volume":"39","author":"Geert-J\u00f6rgensen","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1037\/1528-3542.5.2.131","article-title":"Negative mood, self-focused attention, and the experience of physical symptoms: the joint impact hypothesis","volume":"vol. 5","author":"Gendolla","year":"2005","journal-title":"Emotion"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0300","first-page":"171","article-title":"Contribution to the knowledge of hysteria based on the use of psychotomimetics","volume":"20","author":"Giberti","year":"1959","journal-title":"Arch. Psicol. Neurol. Psichiatr."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0305","first-page":"576","article-title":"Nouveaux Aspects des Exp\u00e9riences Avec des Drogues Psychotropes (LSD-25 et LAE-32) dans les Psychon\u00e9vroses. [New Aspects of Experimenting with Psychotropic Drugs (LSD-25 and LAE-32) in the Psychoneuroses.]","volume":"1","author":"Giberti","year":"1959","journal-title":"Neuro-Psychopharmacology."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0310","first-page":"191","article-title":"Use of lysergic acid diethylamide in psychoneuroses; preliminary observations and principles of diagnostic and therapeutic evaluation","volume":"8","author":"Giberti","year":"1956","journal-title":"Sist. Nerv."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02791072.2021.2022817","article-title":"Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia","volume":"55","author":"Glynos","year":"2023","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0320","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2215-0366(20)30128-0","article-title":"Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial","volume":"7","author":"Goldstein","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0325","article-title":"Evaluating commonalities across medically unexplained symptoms","author":"Guo","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111642_bb0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.15288\/jsad.2020.81.115","article-title":"LSD overdoses: three case reports","volume":"81","author":"Haden","year":"2020","journal-title":"Stud. Alcohol Drugs."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0335","first-page":"279","article-title":"Somatoform disorders and medically unexplained symptoms in primary care: a systematic review and meta-analysis of prevalence","volume":"112","author":"Haller","year":"2015","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0340","doi-asserted-by":"crossref","unstructured":"Hausner M, Dole\u017eal V. Group and individual psychotherapy under LSD. Acta Psychother. Psychosom. JSTOR; 1963;39\u201359.","DOI":"10.1159\/000285664"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0345","first-page":"87","article-title":"Follow-up studies in group and individual LSD psychotherapy","volume":"8","author":"Hausner","year":"1966","journal-title":"Act Nerv. Super (Praha)"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0350","series-title":"Psychother. Psychosom.","first-page":"12","article-title":"Management of Functional Somatic Syndromes and Bodily Distress","author":"Henningsen","year":"2018"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0355","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/ajp.120.4.396","article-title":"Lsd-25 in conversion reaction","volume":"120","author":"Heyder","year":"1963","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0360","author":"Hodgin"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7861\/clinmed.2020-0947","article-title":"Medically unexplained symptoms: assessment and management","volume":"21","author":"Husain","year":"2021","journal-title":"Clin. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059971","article-title":"Prevalence of medically unexplained symptoms in adults who are high users of healthcare services and magnitude of associated costs: a systematic review","author":"Jadhakhan","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0375","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0447.1964.tb04950.x","article-title":"Three years\u2019 experience with the use of LSD as an aid in psychotherapy","volume":"39","author":"Johnsen","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0380","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0385","article-title":"Microbiome-gut-Brian axis modulation: new approaches in treatment of neuropsychological and gastrointestinal functional disorders","author":"Kargbo","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0390","first-page":"109","article-title":"The effectiveness of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease: a case study","volume":"16","author":"Kinderlehrer","year":"2023","journal-title":"Int. Med. Case Rep. J."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010628.pub2","article-title":"Pharmacological interventions for somatoform disorders in adults","author":"Kleinst\u00e4uber","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111642_bb0400","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0277-9536(02)00451-3","article-title":"A symptom perception approach to common physical symptoms","volume":"57","author":"Kolk","year":"2003","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0405","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000337349","article-title":"Economics of medically unexplained symptoms: a systematic review of the literature","author":"Konnopka","year":"2012","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2020.101829","article-title":"Understanding persistent physical symptoms: conceptual integration of psychological expectation models and predictive processing accounts","author":"Kube","year":"2020","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0415","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/08039488.2017.1336251","article-title":"LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark","volume":"71","author":"Larsen","year":"2017","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0420","series-title":"Psychotherapy with hallucinogens. A clinical Report with special reference to the revival of emotional phases of childhood. Proceedings of the Quarterly Meeting of the Royal Medico-Psycho-logical Association in London","first-page":"67","author":"Leuner","year":"1963"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0425","first-page":"253","article-title":"Psychotherapy with the aid of hallucinogenic drugs","volume":"16","author":"Leuner","year":"1966","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0430","series-title":"Present State of Psycholytic Therapy and its Possibilities. The Use of LSD in Psychotherapy and Alcoholism","first-page":"101","author":"Leuner","year":"1967"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0435","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/02698811241248395","article-title":"Exploring psychedelic-assisted therapy in the treatment of functional seizures: a review of underlying mechanisms and associated brain networks","author":"Lewis","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0440","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern Clinical Research on LSD","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0445","series-title":"The Use of Lysergic Acid in Individual Psychotherapy","author":"Ling","year":"1960"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0450","first-page":"201","article-title":"The treatment of anxiety with lysergic acid and methyl phenidate","volume":"191","author":"Ling","year":"1963","journal-title":"Practitioner"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111279","article-title":"Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or long COVID): a comprehensive review","author":"Low","year":"2025","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.genhosppsych.2008.01.001","article-title":"Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment","volume":"30","author":"L\u00f6we","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0465","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0470","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0475","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/08039489609082516","article-title":"Psychotherapy with the aid of LSD","volume":"50","author":"Madsen","year":"1996","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0480","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0485","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/002076406401000301","article-title":"LSD analysis","volume":"10","author":"Martin","year":"1964","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0490","series-title":"The Use of LSD in Psychotherapy and Alcoholism","first-page":"223","article-title":"LSD Analysis","author":"Martin","year":"1967"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0495","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000002149","article-title":"Psychedelic-assisted therapy as a promising treatment for irritable bowel syndrome","author":"Mauney","year":"2025","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0500","first-page":"500","article-title":"Microdosing psychedelics: current evidence from controlled studies","author":"Murphy","year":"2024","journal-title":"Biol. Psychiatry: Cognit. Neurosci. Neuroimaging"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0505","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109232","article-title":"Psychedelics as potent anti-inflammatory therapeutics","author":"Nichols","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0515","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/jnnp-2014-309255","article-title":"Physiotherapy for functional motor disorders: a consensus recommendation","volume":"86","author":"Nielsen","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(24)00135-2","article-title":"Specialist physiotherapy for functional motor disorder in England and Scotland (Physio4FMD): a pragmatic, multicentre, phase 3 randomised controlled trial","author":"Nielsen","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0525","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3999(01)00224-0","article-title":"How many functional somatic syndromes?","volume":"51","author":"Nimnuan","year":"2001","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0530","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/0269881116675754","article-title":"Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future","author":"Nutt","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0535","unstructured":"OCEBM Levels of Evidence \u2014 Centre for Evidence-Based Medicine (CEBM), University of Oxford [Internet]. [cited 2026 Jan 30]. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 30 Jan 2026."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0540","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpsychores.2008.09.018","article-title":"Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review","author":"Olde Hartman","year":"2009","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0545","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1556\/2054.2019.001","article-title":"Long-lasting analgesic effect of the psychedelic drug changa: a case report","volume":"3","author":"Ona","year":"2019","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0550","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0555","series-title":"Medically Unexplained Physical Symptoms (MUPS) among Adults in Canada: Comorbidity, Health Care Use and Employment","author":"Park","year":"2017"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1020505","article-title":"Lower-dose psycholytic therapy \u2013 a neglected approach","author":"Passie","year":"2022","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00626","article-title":"Medically unexplained physical symptoms in hospitalized patients: a 9-year retrospective observational study","volume":"9","author":"Poloni","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0570","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/070674376601100410","article-title":"LSD-25 as an adjunct to long-term psychotherapy","volume":"11","author":"Pos","year":"1966","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0575","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/PSY.0000000000000405","article-title":"Long-term outcome of bodily distress syndrome in primary care: a follow-up study on health care costs, work disability, and self-rated health","volume":"79","author":"Rask","year":"2017","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0580","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/JPR.S439348","article-title":"Scoping review: the role of psychedelics in the management of chronic pain","author":"Robinson","year":"2024","journal-title":"J. Pain Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0585","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0590","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/bjp.103.431.332","article-title":"Further studies in the therapeutic value of lysergic acid diethylamide in mental illness","volume":"103","author":"Sandison","year":"1957","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0595","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1192\/bjp.100.419.491","article-title":"The therapeutic value of lysergic acid diethylamide in mental illness","volume":"100","author":"Sandison","year":"1954","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2023.111155","article-title":"Explanations for functional somatic symptoms across European treatment settings: a mixed methods study","volume":"166","author":"Saunders","year":"2023","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","article-title":"A century of research on psychedelics: a scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs","volume":"64","author":"Solmi","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0610","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005053-197312000-00002","article-title":"The use of LSD in time-limited psychotherapy","volume":"157","author":"Soskin","year":"1973","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0615","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1192\/bjp.109.458.37","article-title":"Permissive group therapy with lysergic acid diethylamide","volume":"109","author":"Spencer","year":"1963","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0620","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0625","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2025.2484380","article-title":"Utilizing psychedelics to enhance well-being: a systematic review","author":"Thomson","year":"2025","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0630","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0635","first-page":"1131","article-title":"LSD y Amfetaminas en Psicoterapia Grupal. [LSD and Amphetamines in Group Psychotherapy.]","volume":"132","author":"Ucha Udabe","year":"1968","journal-title":"Sem. Med."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0640","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1467-9450.00280","article-title":"Learning subjective health complaints","volume":"43","author":"Van Den Bergh","year":"2002","journal-title":"Scand. J. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0645","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neubiorev.2017.01.015","article-title":"Symptoms and the body: taking the inferential leap","author":"Van den Bergh","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0650","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011142","article-title":"Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults","author":"van Dessel","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0655","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0447.1964.tb07495.x","article-title":"Indications and counter-indications for LSD treatment: observations at Powick hospital, England","volume":"40","author":"Vanggaard","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0660","series-title":"Covidence Systematic Review Software. Melbourne, Australia","author":"Veritas Health Innovation","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0665","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0670","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(98)08320-2","article-title":"Functional somatic syndromes: one or many?","volume":"354","author":"Wessely","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0675","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.1964.tb133783.x","article-title":"Lysergic acid diethylamide in psychotherapy","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.pnpbp.2026.111642_bb0680","author":"Wilde"},{"key":"10.1016\/j.pnpbp.2026.111642_bb0685","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/13634615221129115","article-title":"Microdosing with classical psychedelics: research trajectories and practical considerations","author":"Wong","year":"2022","journal-title":"Transcult. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:33:22Z","timestamp":1776494002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":137,"alternative-id":["S0278584626000382"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111642","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics in functional disorders: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111642"}}